ALIGN TECHNOLOGY INC Q3 FY2026 earnings call

• CEO Succession: Announced that Joe Hogan will step down as CEO, with Jennifer Davis appointed as the next CEO, joining November 2nd and assuming the role December 31st.
• Q3 Operational Highlights: Achieved record doctor submitters (91,000, up >3%) and record clear aligner shipments (691,000, up 6.6%). Utilization increased 3.4%. Non-GAAP operating margin reached 24.4%, exceeding expectations due to disciplined expense management.
• Regional Performance:
  • Americas: North America orthodontist shipments grew YoY for the first time in six quarters, supported by DSOs. Latin America saw double-digit growth.
  • EMEA: Double-digit shipment growth driven by strong utilization and DSO expansion.
  • APAC: Double-digit sequential and YoY growth, led by China teen demand and retail channel strength.
• Strategic Initiatives:
  • Digital Platform: Expanding integration of iTero, AI planning, and ExoCAD restorative workflows (Invisalign ART) to engage GP dentists beyond traditional orthodontics.
  • Affordability: Triple-digit growth in 'zero additional aligner' volume; partnerships with Healthcare Finance Direct and CareCredit pilots to improve patient conversion.
  • Product Innovation: Launching US pilot for custom 3D-printed Sports Mouthguards using NXT technology; expanding younger patient treatments (Invisalign First, Palatal Expanders).
• Elliott Management Collaboration: Welcomed independent director Quinton Blackford; ongoing review focused on commercial effectiveness, scalability, and North America performance improvement.

Clear Aligner: Revenue was $839.3 million, down 2.3% year-over-year (or 1.8% at constant currency), representing approximately 82.7% of total revenue. This decline was primarily driven by a shift toward lower-priced countries/products and higher discounts, partially offset by price increases. Systems and Services: Revenue was $175.5 million, down 7.6% year-over-year (or 7.1% at constant currency), representing approximately 17.3% of total revenue. This decrease reflects a strategic mix shift toward lower-price scanner configurations and flexible acquisition models (leasing, rentals). Total Worldwide Revenue: $1.015 billion, up 1.9% year-over-year (or 2.4% at constant currency).

• Q4 2026 Revenue: Expected range of $1.00 billion to $1.02 billion.
• Q4 2026 Clear Aligner Volume: Expected to increase low single digits year-over-year.
• Q4 2026 Clear Aligner ASP: Expected to decrease approximately 1% year-over-year.
• Q4 2026 Systems & Services Revenue: Expected range of $170 million to $180 million.
• Q4 2026 Margins: GAAP Gross Margin ~71%; Non-GAAP Gross Margin ~72%; GAAP Operating Margin ~20%; Non-GAAP Operating Margin ~26%.
• Fiscal 2026 Full Year Revenue: Approximately $4.11 billion to $4.13 billion (downward revision from prior outlook).
• Fiscal 2026 Clear Aligner Growth: Volume and revenue expected to grow ~5-6% year-over-year.
• Fiscal 2026 Systems & Services Revenue: Expected $715 million to $725 million.
• Fiscal 2026 Operating Margins: GAAP ~16.2%; Non-GAAP ~23.7% (improvement of ~100 bps YoY).
• Capital Allocation: Expect capital expenditures of $125-$150 million; expect to repurchase ~$500 million of common stock in 2026.
• 2027 Outlook: Preliminary expectation for continued revenue growth and non-GAAP operating margin improvement of at least 100 basis points, assuming current macro conditions persist without consumer recovery.

• Macroeconomic Headwinds: Continued softness in discretionary healthcare spending and capital equipment investment globally, particularly affecting North American GP retail channels.
• Pricing Pressure: Shift toward lower-priced scanner configurations and flexible acquisition models impacting reported revenue and ASPs, though like-for-like pricing has stabilized.
• China VBP Exposure: Potential impact of Value-Based Procurement policies in China; while currently mostly private market exposure (~15% public), expansion into public/private sectors could affect pricing dynamics.
• Consumer Affordability: Patient interest remains high, but affordability barriers hinder treatment starts, requiring reliance on financing solutions which are still maturing in some regions.

Q: Analyst asked about factors driving Q4 guidance vs Q3 strength, specifically regarding case starts and macro indicators. / A: Management cited a broad-based reticent consumer environment globally, not just in North America. They emphasized that the challenging market conditions persisted through Q3 and are factored into Q4 guidance, noting no singular variable but rather a consistent trend of cautious discretionary spending.